EUVIMEDEUVIMED entdecken
Crossref

How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience

Marc A Rodwin iD

International Journal of Health Services · 2021-04 · 51 (2) · 229-237

DOI: 10.1177/0020731421997094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Health Services, online erschienen am 25.03.2021. Verfasst von Marc A Rodwin. Beteiligte Einrichtung: Law School, 1850Suffolk University, Boston, MA, USA. Hauptthemen laut MEDLINE: Drug Costs, State Medicine. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To control costs and improve access, nations can adopt strategies employed in the United Kingdom to control pharmaceutical prices and spending. Current policy evolved from a system created in 1957 that allowed manufacturers to set launch prices, capped manufacturers’ rates of return, and later cut list prices. These policies did not effectively control spending and had limited effects on purchase prices. The United Kingdom currently controls pharmaceutical spending in 4 ways. (a) Since 1999, it has typically paid no more than is cost-effective. (b) Since 2017, for medicines that will have a significant budget impact, National Health Service England seeks discounts from cost-effective prices or seeks to limit access for 2 years to patients with the greatest need. (c) Since 2014, statutes and a voluntary scheme have required branded manufacturers to pay the government rebates to recoup the difference between the global pharmaceutical budget and actual spending. (d) For hospitals, generics and some patented drugs are procured through competitive bidding; community pharmacies are reimbursed through a system that provides an incentive to beat average generic market prices. These policies controlled the growth of spending, with the largest effects following budget controls in 2014. Changes since 2008 have reduced savings, first by paying more than is cost-effective for cancer drugs and then by applying higher cost-effectiveness thresholds for some drugs used to treat cancer and certain other drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CostsState MedicineCosts and Cost AnalysisDrugs, GenericHumansUnited Kingdom

Stichwörter der Autor:innen

HTAbudgetscomparative effectivenesscost controlcost-effectivenesspharmaceuticalsprice control

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • Law School, 1850Suffolk University, Boston, MA, USA.

ORCID-Profile: Marc A Rodwin

Zitieren

APA

Rodwin, M. A. (2021). How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience. International Journal of Health Services, 51(2), 229-237. https://doi.org/10.1177/0020731421997094

Vancouver

Rodwin MA. How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience. International Journal of Health Services. 2021;51(2):229-237. doi:10.1177/0020731421997094

BibTeX
@article{Rodwin2021,
  author = {Rodwin, Marc A},
  title = {How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its Experience},
  journal = {International Journal of Health Services},
  year = {2021},
  volume = {51},
  number = {2},
  pages = {229--237},
  doi = {10.1177/0020731421997094}
}
Kostenlos starten →